Hub · Are peptides legal in Australia? Research peptide schedule status

What is the status of the retatrutide TRIUMPH-OUTCOMES trial?

ClinicalTrials.gov NCT06383390 lists the retatrutide TRIUMPH-OUTCOMES trial as Phase 3 and Active, not recruiting, with no registry results posted. The record's latest update was posted on 8 October 2026. Its primary and overall study completion dates are both estimated as February 2029. These fields were read on 15 October 2026; estimated dates are not completed milestones.

Published 2026-10-15Updated 2026-10-15Written by Form Laboratories research team2 min read

01What status does…Contents

TRIUMPH-OUTCOMES has a separate registry number: NCT06383390. The October 2026 ClinicalTrials.gov entry describes retatrutide Phase 3 research sponsored by Eli Lilly and Company; the record update was posted on 8 October 2026 (read 15 October 2026).

Key facts

Key facts for What is the status of the retatrutide TRIUMPH-OUTCOMES trial?
Registry entry	ClinicalTrials.gov NCT06383390, read 15 October 2026
Study name	TRIUMPH-OUTCOMES
Substance	Retatrutide (ClinicalTrials.gov NCT06383390)
Phase and status	Phase 3; Active, not recruiting (record updated 8 October 2026)
Actual study start	30 April 2024 (ClinicalTrials.gov NCT06383390)
Estimated primary and study completion	February 2029 (ClinicalTrials.gov NCT06383390)
Registry results	No results posted (record read 15 October 2026)

ClinicalTrials.gov NCT06383390, update posted 8 October 2026; read 15 October 2026

What status does NCT06383390 record?

ClinicalTrials.gov NCT06383390 records the retatrutide TRIUMPH-OUTCOMES study as Active, not recruiting and Phase 3. The record names Eli Lilly and Company as lead sponsor and gives an actual start date of 30 April 2024. Its latest update was posted on 8 October 2026; these fields were checked on 15 October 2026.

This trial-status entry belongs to Peptides and Australian Law. The Schedule 4 explainer concerns the separate scheduling record. The tirzepatide PBAC decision concerns a committee recommendation rather than this trial entry.

ClinicalTrials.gov NCT06383390, read 15 October 2026Giblin et al., TRIUMPH design paper, first published 15 October 2025

Are completion dates actual, and are registry results posted?

The retatrutide TRIUMPH-OUTCOMES record, NCT06383390, gives February 2029 as the estimated date for both primary completion and overall study completion. Neither field is marked Actual. ClinicalTrials.gov shows no results posted for this entry in the record read on 15 October 2026, whose latest update was posted on 8 October 2026.

Giblin et al.'s TRIUMPH design paper, first published on 15 October 2025, describes TRIUMPH-1 through TRIUMPH-4; its abstract does not report TRIUMPH-OUTCOMES results (Diabetes, Obesity and Metabolism, January 2026 issue). The semaglutide PBAC decision is a separate dated status record.

FAQ

What is the registry number for retatrutide TRIUMPH-OUTCOMES?

ClinicalTrials.gov identifies retatrutide TRIUMPH-OUTCOMES as NCT06383390 (update posted 8 October 2026, read 15 October 2026).

Does this registry entry post results?

No. NCT06383390 posts no registry results for retatrutide TRIUMPH-OUTCOMES in the record read on 15 October 2026 (update posted 8 October 2026).

More in this hub

Are peptides legal in Australia? Research peptide schedule status

Citations

1 sources

Giblin K, Kaplan LM, Somers VK, et al. Diabetes, Obesity and Metabolism. 2026;28:83-93. TRIUMPH-1 through TRIUMPH-4: rationale and design; first published 15 October 2025.
doi:10.1111/dom.70209

Written by

Form Laboratories research team

Perth, Western Australia. We supply research-use-only reference material. Available reports cover historical samples; current batch certification is unverified.

Written in-house: These articles are written and maintained by our own research team, not by a named clinician.
Built from the record: Every figure comes from published literature, listed in full above with a link to the original paper.
No use directions: We describe what the research measured. We never give dosing, preparation, or advice.

How we produce these guides Research library

Form Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.